---
title: "BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295066106.md"
description: "BillionToOne (NASDAQ: BLLN) shares fell 28.12% in after-hours trading following its Q2 earnings report, despite a 5.43% regular session gain. The company reported Q2 revenue of $109.4 million and net income of $8.1 million, marking a turnaround from last year's loss. While maintaining full-year revenue guidance, the stock drop occurred alongside announcements of upcoming product launches for Unity Fetal Risk Screen and Northstar Origin."
datetime: "2026-08-06T06:01:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295066106.md)
  - [en](https://longbridge.com/en/news/295066106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295066106.md)
---

# BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move

**BillionToOne, Inc.** (NASDAQ:BLLN) shares fell 28.12% in Wednesday’s after-hours session after the company reported its second-quarter financial results.

The stock closed Wednesday’s regular session up 5.43% at $149.97 before falling 28.12% to $107.80 in after-hours trading.

BillionToOne is a molecular diagnostics company that develops genetic testing products for prenatal and oncology applications using its proprietary DNA counting technology.

## **Quarter Results**

For the quarter ended June 30, 2026, BillionToOne reported revenue of $109.4 million, up from $66.6 million in the prior-year period. Net income was $8.1 million, or $0.15 per diluted share, compared with a net loss of $0.2 million, or $(0.02) per diluted share, a year earlier.

The company delivered 196,000 tests during the quarter, a 35% increase from a year ago, while gross profit margin improved to 70% from 65%. Income from operations was $5.5 million, compared with an operating loss of $1.6 million in the prior-year period.

BillionToOne maintained its full-year 2026 revenue guidance of $450 million to $465 million and said it expects to continue generating profitability while investing in the business. The company also announced the upcoming commercial launches of its expanded Unity Fetal Risk Screen on Aug. 17 and **Northstar Origin** on Sept. 1.

**Read Also: Paranovus Entertainment Technology (PAVS) Stock Rallies Over 34% After Hours: Here's What Is Going On**

## **Trading Metrics**

BillionToOne has a market capitalization of approximately $6.90 billion, with a 52-week high of $150.44 and a 52-week low of $61.96.

Over the past 12 months, BLLN shares have gained approximately 37.66%.

**Benzinga Edge Stock Rankings** show **positive price trends** across the short-, medium- and long-term time frames.

_**Disclaimer:** This content was produced with the help of AI tools and was reviewed and published by Benzinga editors._

**Read Also: Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move**

_Photo: Who is Danny/Shutterstock_

### Related Stocks

- [BLLN.US](https://longbridge.com/en/quote/BLLN.US.md)
- [PAVS.US](https://longbridge.com/en/quote/PAVS.US.md)
- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)

## Related News & Research

- [BillionToOne Chief Product Officer Sakakibara Shan Riku disposes of 4,000 common shares worth $560,840](https://longbridge.com/en/news/294868285.md)
- [BillionToOne: Buy Rating Reaffirmed on Strong Q2 Beat, 2027 Growth Visibility, and Attractive Valuation vs. High-Growth Peers](https://longbridge.com/en/news/295146302.md)
- [Urban Edge 2Q26 net income drops to 17,922; revenue rises 7.65% to 122.78 million](https://longbridge.com/en/news/295141705.md)
- [DNA: Q2 2026 revenue dropped 48% year-over-year, with major autonomous lab contracts secured](https://longbridge.com/en/news/295007946.md)
- [Lucid Diagnostics wins Concert coverage policy for EsoGuard esophageal DNA test across client health plans](https://longbridge.com/en/news/294970219.md)